Intercept Stock Price Skyrockets On Continuing Stream Of Good Data For OCA Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Early stop due to efficacy of NIH Phase II trial in non-alcoholic steatohepatitis could mean quick pathway to approval for compound in this unmet medical need. A growing liver disease, Intercept believes NASH is an under-recognized opportunity, which could outstrip HCV and cirrhosis as a cause of liver transplantation.